The total return over the past 12 months is +3.79% vs. +16.94% for the S&P 500. So far it's up -3.18% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +3.79% | (12.97%) | (5.59%) | (4.98%) | +3.87% | +6.55% |
| Total Return CAGR | +3.79% | (12.97%) | (5.59%) | (4.98%) | +3.87% | +6.55% |
| Revenue CAGR | +11.20% | +15.09% | +12.19% | +13.34% | +14.98% | +22.99% |
| Net Income CAGR | (88.90%) | (9.97%) | (38.62%) | N/A | N/A | N/A |
| EPS CAGR | (88.99%) | +33.78% | (17.46%) | N/A | N/A | N/A |
| Free Cash Flow CAGR | +5.99% | +161.60% | +33.84% | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +11.78% | +74.50% | +26.08% | N/A | +44.74% | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
BioMarin Pharmaceutical Inc. (BMRN)
| Year | Start price | End price | BMRN Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $59.43 | $57.54 | (3.18%) | +14.51% | (17.69%) |
| 2025 | $65.73 | $59.43 | (9.58%) | +17.72% | (27.30%) |
| 2024 | $96.42 | $65.73 | (31.83%) | +24.89% | (56.72%) |
| 2023 | $103.49 | $96.42 | (6.83%) | +26.19% | (33.02%) |
| 2022 | $88.35 | $103.49 | +17.14% | (18.17%) | +35.31% |
| 2021 | $87.69 | $88.35 | +0.75% | +28.74% | (27.99%) |
| 2020 | $84.55 | $87.69 | +3.71% | +18.37% | (14.66%) |
| 2019 | $85.15 | $84.55 | (0.70%) | +31.22% | (31.92%) |
| 2018 | $89.17 | $85.15 | (4.51%) | (4.56%) | +0.05% |
| 2017 | $82.84 | $89.17 | +7.64% | +21.70% | (14.06%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
